Researchers reveal a crucial process in the working of the immune system

VIB researchers show how dendritic cells mature without causing an immune response

Ghent, 15 May – For our immune system to initiate a response to an infection, cells called dendritic cells have to present antigens to T cells. This shows the T cells where to focus their efforts and helps clear the infection. In normal conditions, however, dendritic cells shouldn't activate the immune system or else autoimmune conditions arise. New work by the teams of profs. Yvan Saeys, Kodi Ravichandran, Bart Lambrecht, and Sophie Janssens (VIB-UGent Center for Inflammation Research) reveals how dendritic cells mature without causing an immune response. Their work appears in Science Immunology and has ramifications for the treatment of various autoimmune disorders.  

Raising the flag (in peacetime) 

Think of the immune system as an army with regiments of different cell types that have to work together to protect the rest of the body from bacterial or viral invaders. T cells are a group of diverse cells that we can consider as the infantry of our immune army. But they have to learn how to recognize the invaders first. 

That's where the dendritic cells (or DCs) come in. DCs function a bit like spies; they venture onto the battlefield, steal little pieces of the invaders (antigens) and bring them back to the T cells. Then, with these antigens, the T cells have the information they need to recognize, target, and destroy the invading bacteria or viruses. After finding and presenting antigens, DCs undergo a process of maturation. 

Even when our body is in peacetime, dendritic cells mature, which helps prevent autoimmune reactions. This is called tolerogenic maturation. How it works, though, is a mystery. Until now. 

Victor Bosteels (VIB-UGent), co-first author of the study: "The pathways driving immunogenic maturation in response to infectious insults are well-characterized, but the signals that drive tolerogenic maturation during homeostasis are still poorly understood. So, we decided to map the molecular processes that drive tolerogenic DC maturation." 

Engulfment and cholesterol 

First, the researchers confirmed that, indeed, DCs undergo maturation without being exposed to infectious stimuli in mouse models. Digging deeper, they also figured out how that process takes place. 

Sandra Maréchal (VIB-UGent), co-first author: "We found that the engulfment of apoptotic cells – cells that die as a normal part of bodily maintenance, so to speak – is necessary and sufficient to trigger DC maturation. By using a single-cell technology called CITE Seq, we unraveled the genetic program behind this process and discovered that maturing DCs activate genes that help them remove cholesterol from inside their cell bodies." 
Summary figure of the findings. Created with BioRender.com.

With this knowledge of DC maturation in hand, the researchers took it one step further and they figured out how to mimic this process. By 'feeding' DCs empty lipid nanoparticles they could kickstart the maturation process, which suggests that the uptake of exogenous lipids, rather than the process of engulfment, is sufficient to drive the maturation program. 

Prof. Sophie Janssens (VIB-UGent), who led the study: "Our work has important implications for our understanding of the immune system in autoimmune conditions. We are hopeful that our research will lead to new insights into the role of dendritic cells in immune function, and ultimately to the development of new therapies for these and other diseases." 

Publication 

Bosteels, Maréchal, et al. LXR signaling controls homeostatic dendritic cell maturation. Science Immunology, 2023. 


Questions from patients  

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address. 


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be